149 related articles for article (PubMed ID: 10429984)
1. Expression of the psoriasis-associated antigen, Pso p27, is inhibited by cyclosporin A.
Dalaker M; Jacobsen T; Lysvand H; Iversen OJ
Acta Derm Venereol; 1999 Jul; 79(4):281-4. PubMed ID: 10429984
[TBL] [Abstract][Full Text] [Related]
2. Expression of the psoriasis-associated antigen, Pso p27, is inhibited by traditional Chinese medicine.
Song P; Lysvand H; Yuhe Y; Liu W; Iversen OJ
J Ethnopharmacol; 2010 Jan; 127(1):171-4. PubMed ID: 19781613
[TBL] [Abstract][Full Text] [Related]
3. Use of scale antibodies for the detection of antigens in psoriatic lesions.
Iversen OJ; Bergh K; Lysvand H
Acta Derm Venereol; 1993 Feb; 73(1):31-4. PubMed ID: 8095747
[TBL] [Abstract][Full Text] [Related]
4. The psoriasis-associated antigen, pso p27, participates in the formation of complement activating immune-complexes in psoriatic scale.
Asbakk K; Bergh K; Iversen OJ
APMIS; 1990 Feb; 98(2):143-9. PubMed ID: 2302350
[TBL] [Abstract][Full Text] [Related]
5. Ultrastructural findings and tumor necrosis factor-alpha and intercellular adhesion molecule-1 expression in psoriasis patients before and after oral cyclosporin A therapy.
Eşrefoğlu M; Gül M; Seyhan M
Ultrastruct Pathol; 2006; 30(1):95-102. PubMed ID: 16517475
[TBL] [Abstract][Full Text] [Related]
6. Psoriasis pathogenesis - Pso p27 is generated from SCCA1 with chymase.
Lysvand H; Hagen L; Klubicka L; Slupphaug G; Iversen OJ
Biochim Biophys Acta; 2014 May; 1842(5):734-8. PubMed ID: 24560885
[TBL] [Abstract][Full Text] [Related]
7. Pso p27, a SERPINB3/B4-derived protein, is most likely a common autoantigen in chronic inflammatory diseases.
Iversen OJ; Lysvand H; Slupphaug G
Clin Immunol; 2017 Jan; 174():10-17. PubMed ID: 27871892
[TBL] [Abstract][Full Text] [Related]
8. Higher levels of antibodies against the psoriasis-associated antigen pso p27 in cerebrospinal fluid from patients with low back pain and sciatica.
Zwart JA; Iversen OJ; Sand T; Dale LG; Unsgård G
Spine (Phila Pa 1976); 1999 Feb; 24(4):373-7. PubMed ID: 10065522
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporin in childhood psoriasis.
Perrett CM; Ilchyshyn A; Berth-Jones J
J Dermatolog Treat; 2003 Jun; 14(2):113-8. PubMed ID: 12775319
[TBL] [Abstract][Full Text] [Related]
10. The expression of retrovirus-like particles in psoriasis.
Iversen OJ
J Invest Dermatol; 1990 Nov; 95(5 Suppl):41S-43S. PubMed ID: 16788630
[TBL] [Abstract][Full Text] [Related]
11. Altered expression of the alpha2 laminin chain in psoriatic skin: the effect of treatment with cyclosporin.
Toti P; Pellegrino M; Villanova M; Flori ML; Miracco C; Bartolommei S; Andreassi L
Br J Dermatol; 1998 Sep; 139(3):375-9. PubMed ID: 9767280
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with the use of cyclosporin A in psoriasis. Results of a retrospective study.
Ojeda R; Sánchez Regaña M; Massana J; Oliete R; Umbert P
J Dermatolog Treat; 2005; 16(4):238-41. PubMed ID: 16249146
[TBL] [Abstract][Full Text] [Related]
13. Hypodermal Adipose Tissue Sonoelastography for Monitoring Treatment Response in Patients with Plaque Psoriasis.
Dattola A; Altobelli S; Marsico S; Plastina D; Nistico SP; Cavallo A; Floris R; Bianchi L; Guazzaroni M
Photomed Laser Surg; 2017 Sep; 35(9):484-491. PubMed ID: 28445107
[TBL] [Abstract][Full Text] [Related]
14. The correlation between response to oral cyclosporin therapy and systemic inflammation, metabolic abnormality in patients with psoriasis.
Ohtsuka T
Arch Dermatol Res; 2008 Nov; 300(10):545-50. PubMed ID: 18797895
[TBL] [Abstract][Full Text] [Related]
15. Quality of life improvement in treatment of psoriasis with intermittent short course cyclosporin (Neoral).
Salek MS; Finlay AY; Lewis JJ; Sumner MI
Qual Life Res; 2004 Feb; 13(1):91-5. PubMed ID: 15058791
[TBL] [Abstract][Full Text] [Related]
16. Sequential study on the treatment of moderate-to-severe chronic plaque psoriasis with mycophenolate mofetil and cyclosporin.
Pedraz J; Daudén E; Delgado-Jiménez Y; García-Río I; García-Díez A
J Eur Acad Dermatol Venereol; 2006 Jul; 20(6):702-6. PubMed ID: 16836499
[TBL] [Abstract][Full Text] [Related]
17. Cyclin D1, B and A expression and cell turnover in psoriatic skin lesions before and after cyclosporin treatment.
Miracco C; Pellegrino M; Flori ML; Vatti R; Materno M; Andreassi L
Br J Dermatol; 2000 Nov; 143(5):950-6. PubMed ID: 11069501
[TBL] [Abstract][Full Text] [Related]
18. The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis.
Otkjaer K; Kragballe K; Funding AT; Clausen JT; Noerby PL; Steiniche T; Iversen L
Br J Dermatol; 2005 Nov; 153(5):911-8. PubMed ID: 16225599
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis, P53 and Bcl-2 expression in response to topical calcipotriol therapy for psoriasis.
El-Domyati M; Barakat M; Abdel-Razek R; El-Din Anbar T
Int J Dermatol; 2007 May; 46(5):468-74. PubMed ID: 17472673
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of calcipotriol ointment applied under hydrocolloid occlusion in psoriasis.
Castelijns FA; Gerritsen MJ; van Erp PE; van de Kerkhof PC
Dermatology; 2000; 200(1):25-30. PubMed ID: 10681609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
